| |
Cases(%) (n=19) |
Controls (%) (n=15) |
| Sex (male:female) |
11:8 |
10:6 |
| Age (median, range) |
50.69 (19.0-62.8) |
30.37(16.4-65.2) |
Type of leukemia
AML
ALL |
12(63.2)
7 (36.8) |
10 (66.7)
5 (33.3) |
Chemotherapy in admission in which IMI was diagnosed*^
Induction
Consolidation
Mobilisation |
15 (78.9)
4 (21.1)
0 |
9 (60.0)
5 (33.3)
1 (6.7) |
Duration of neutropenia^
>/=14d
<14d |
13 (86.7)
2 (13.3) |
1 (6.7)
14 (93.3) |
Duration ANC <100/mm3^
>/=10d
<10d |
15 (78.9)
4 (21.1) |
5 (33.3)
10 (66.7) |
ANC at diagnosis of leukemia
>/=500/mm3
<500/mm3 |
8 (42.1)
11 (57.9) |
13 (86.7)
2(13.3) |
Absolute monocyte count #*
<120/mm3
>120/mm3
|
9 (47.4)
10 (52.6) |
11 (73.3)
3 (20.0) |
| No. given FQ prophylaxis |
9 (47.4) |
9 (60) |
| No. given ITC prophylaxis |
14 (73.7) |
12 (80) |
| No. given syrup ITC |
14 (73.7) |
14 (93.3) |
| Anti-fungal prophylaxis >14days |
5 (26.3) |
8(53.3) |
| Median LOS (days) |
46 (22-88) |
23 (9-65) |
* for controls, this was the chemotherapy received in the month (± 1 month) in
which the IMD in the matched case was diagnosed